Cryopreservation and Revival of Human Mesenchymal Stromal Cells

Part of the Methods in Molecular Biology book series (MIMB, volume 1416)


Cell-based therapy is a promising and innovative new treatment for different degenerative and autoimmune diseases, and mesenchymal stromal cells (MSCs) from the bone marrow have demonstrated great therapeutic potential due to their immunosuppressive and regenerative capacities.

The establishment of methods for large-scale expansion of clinical-grade MSCs in vitro has paved the way for their therapeutic use in clinical trials. However, the clinical application of MSCs also requires cryopreservation and banking of the cell products. To preserve autologous or allogeneic MSCs for future clinical applications, a reliable and effective cryopreservation method is required.

Developing a successful cryopreservation protocol for clinical stem cell products, cryopreservation media, cryoprotectant agents (CPAs), the freezing container, the freezing temperature, and the cooling and warming rate are all aspects which should be considered.

A major challenge is the selection of a suitable cryoprotectant which is able to penetrate the cells and yet has low toxicity.

This chapter focuses on recent technological developments relevant for the cryopreservation of MSCs using the most commonly used cryopreservation medium containing DMSO and animal serum or human-derived products for research use and the animal protein-free cryopreservation media CryoStor (BioLife Solutions) for clinical use.

Key words

Mesenchymal stromal cells Cryopreservation Cryoprotectant DMSO Cooling rate Viability Cell recovery 



The Aase and Ejnar Danielsens Foundation and the Research Foundation at Rigshospitalet supported the development of this protocol.


  1. 1.
    Bieback K, Kinzebach S, Karagianni M (2011) Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int 2010:193519PubMedPubMedCentralGoogle Scholar
  2. 2.
    Sensebe L, Bourin P, Tarte K (2011) Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 22:19–26CrossRefPubMedGoogle Scholar
  3. 3.
    Haack-Sorensen M, Friis T, Mathiasen AB et al (2013) Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. Cell Transplant 22:521–528CrossRefPubMedGoogle Scholar
  4. 4.
    Le BK, Frassoni F, Ball L et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579–1586CrossRefGoogle Scholar
  5. 5.
    Mathiasen AB, Jorgensen E, Qayyum AA et al (2012) Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells in chronic ischemic heart failure (MSC-HF trial). Am Heart J 164:285–291CrossRefPubMedGoogle Scholar
  6. 6.
    Ra JC, Kang SK, Shin IS et al (2011) Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 9:181PubMedPubMedCentralGoogle Scholar
  7. 7.
    Thirumala S, Goebel WS, Woods EJ (2013) Manufacturing and banking of mesenchymal stem cells. Expert Opin Biol Ther 13:673–691CrossRefPubMedGoogle Scholar
  8. 8.
    Pegg DE (2015) Principles of cryopreservation. Methods Mol Biol 1257:3–19CrossRefPubMedGoogle Scholar
  9. 9.
    Balci D, Can A (2013) The assessment of cryopreservation conditions for human umbilical cord stroma-derived mesenchymal stem cells towards a potential use for stem cell banking. Curr Stem Cell Res Ther 8:60–72CrossRefPubMedGoogle Scholar
  10. 10.
    Janz FL, Debes AA, Cavaglieri RC et al (2012) Evaluation of distinct freezing methods and cryoprotectants for human amniotic fluid stem cells cryopreservation. J Biomed Biotechnol 2012:649353CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Thirumala S, Goebel WS, Woods EJ (2009) Clinical grade adult stem cell banking. Organogenesis 5:143–154CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Li Y, Lu RH, Luo GF, Pang WJ et al (2006) Effects of different cryoprotectants on the viability and biological characteristics of porcine preadipocyte. Cryobiology 53:240–247CrossRefPubMedGoogle Scholar
  13. 13.
    Liu Y, Xu X, Ma X et al (2010) Cryopreservation of human bone marrow-derived mesenchymal stem cells with reduced dimethylsulfoxide and well-defined freezing solutions. Biotechnol Prog 26:1635–1643CrossRefPubMedGoogle Scholar
  14. 14.
    Rowley SD, Feng Z, Chen L et al (2003) A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant 31:1043–1051CrossRefPubMedGoogle Scholar
  15. 15.
    Thirumala S, Gimble JM, Devireddy RV (2010) Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum-free freezing media for cryopreservation of adipose-derived adult stem cells. Stem Cells Dev 19:513–522CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Freimark D, Sehl C, Weber C et al (2011) Systematic parameter optimization of a Me(2)SO- and serum-free cryopreservation protocol for human mesenchymal stem cells. Cryobiology 63:67–75CrossRefPubMedGoogle Scholar
  17. 17.
    Ginis I, Grinblat B, Shirvan MH (2012) Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium. Tissue Eng Part C Methods 18:453–463CrossRefPubMedGoogle Scholar
  18. 18.
    Woods EJ, Thirumala S (2011) Packaging considerations for biopreservation. Transfus Med Hemother 38:149–156CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Acker JP, Croteau IM (2004) Pre- and post-thaw assessment of intracellular ice formation. J Microsc 215(Pt 2):131–138CrossRefPubMedGoogle Scholar
  20. 20.
    Heng BC (2009) Effect of Rho-associated kinase (ROCK) inhibitor Y-27632 on the post-thaw viability of cryopreserved human bone marrow-derived mesenchymal stem cells. Tissue Cell 41(5):376–380CrossRefPubMedGoogle Scholar
  21. 21.
    Haack-Sorensen M, Friis T, Bindslev L et al (2008) Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy. Scand J Clin Lab Invest 68:192–203CrossRefPubMedGoogle Scholar
  22. 22.
    Bieback K, Hecker A, Kocaomer A et al (2009) Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27:2331–2341CrossRefPubMedGoogle Scholar
  23. 23.
    Castiglia S, Mareschi K, Labanca L et al (2014) Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in good manufacturing practice conditions. Cytotherapy 16:750–763CrossRefPubMedGoogle Scholar
  24. 24.
    Perez-Ilzarbe M, Diez-Campelo M, Aranda P et al (2009) Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion 49:1901–1910CrossRefPubMedGoogle Scholar
  25. 25.
    Hubel A (2001) Cryopreservation of HPCs for clinical use. Transfusion 41:579–580CrossRefPubMedGoogle Scholar
  26. 26.
    Mamidi MK, Singh G, Husin JM et al (2012) Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications. J Transl Med 10:229CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Carvalho KA, Cury CC, Oliveira L et al (2008) Evaluation of bone marrow mesenchymal stem cell standard cryopreservation procedure efficiency. Transplant Proc 40:839–841CrossRefPubMedGoogle Scholar
  28. 28.
    Cox MA, Kastrup J, Hrubisko M (2012) Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide. Cell Tissue Bank 13:203–215CrossRefPubMedGoogle Scholar
  29. 29.
    Hirata AA (1968) Cytolytic antibody assay by tryptic digestion of injured cells and electronic counting. J Immunol 91:625–632Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Cardiology Stem Cell Centre, The Heart CentreRigshospitalet Copenhagen University HospitalCopenhagen ØDenmark

Personalised recommendations